Abstract:Background: Hepatic inflammatory and fibrotic lesions promote the development of cirrhosir and hepatocellular carcinoma in patients with chronic Hepatitis 8 (CHB). Farly recognition of hepatic histopathological changes and timely initiation of antivical therapy can delay or even reverse disease progression. Objectives: This study aimed to analyze non invasive diagnostic indicators associated inch different inflammation grades, fibrosis stages, and Hepatios degrees in CHB patients, and their outcomes after antiviral therapy Methods: A total of si CHB patients treated at the Third People's Hospital of Shenzhen from January December 2019 were selected for inflammation grading (G) and fibrous staging (5) based on liver puncture examination results. The patients were further dirnded into mild, moderate, and severe chronic Hepatitis groups. Correlation analysis was conducted via Spearman. The diagnostic performance of the relevant indexes for inflammation grading, bibrosi staging, and Hepatios degree grading was evaluated using receiver operator characteristics (ROC) The performance of different ROC curves was further compared using the DeLong rest. The effects of of antiviral drugs on patients with different liver hutopathological degrees were comparatively analyzed after 24, 48, 72, and 95 weeks. Results: Data analysis at baseline showed that 86.81% (79 of 91) of all patients were male. Additionally, about 61.54% (16 of 26), 30.77% (8 of 26), 85.19% (23 of 27), and 62.96% (17 of 27) of patients with normal ALT had G >= 2, G >= 3, S >= 2, and S >= 3, respectively inflammation grade, fibrosis stage, and Hepatitis degree were positively correlated with portal vein internal diameter, spleen thickness. LN, GPR, FIB-4, and 5 index, and negatively correlated with PLT (P<0.05). The area under the curve (AUC) of the ROC assessed multifactorial combinations PSUPTL, PSWPAHPCL, and PSWPHCL for predicting the risk of developing G3 inflammation, 5:3 fibrosis, and moderate to severe Hepatitis in patients with CHB were 0.806, 0.843, and 0.778, respectively. The diagnostic accuracies were higher than some of these factors applied indindually and some commonly used serological markers. HBV DNA levels were significantly lower in different Hepatitis groups after 24 werks of antiviral therapy than before treatment (P<0.05). Furthermore, the ALT normalization rate and HBV DNA clearance rate were slightly higher in the moderate and severe groups than in the mild group alter 48 werks of treatment (P>0.05). The serum liepatitis B envelope antigen (HBeAg) level was nguficantly lower in the severe group than in the mild group after 72 weeks of antiviral therapy (H7.043, P=0.030). Although only the HBeAg serologic conversion rate was significantly different at 96 weeks among the three groups (chi(2) = 12389,P=0.002), (BeAg negative and the serologic conversion rates higher in the severe group at each time point than in the mild and moderate groups Conclusions: Multiple non invasive indicators are strongly associated with different degrees of liver histopathology in patients with chronic HBV infection. Therefore, PSBPTL, PSWPAHPCI, and PSWPHCL can be used to predict the risk of developing Gas inflammation, 53 fibrosis, and moderate to severe Hepatitis in these pacients, respectively. Moreover, short term anuviral therapy has a more pronounced effect on patients with severe Hepatitis by improving hepatic inflammation and inhibiting viral replication.

Early Diagnosis of Bacterial and Fungal Infection in Chronic Cholestatic Hepatitis B.

Serum CHI3L1 As a Biomarker for Non-invasive Diagnosis of Liver Fibrosis.

Efficiency of Double Plasma Molecular Absorption System on the Acute Severe Cholestatic Hepatitis.

Consensus on the Diagnosis and Treatment of Cholestatic Liver Diseases (2015, China)

Serum metabolomic signatures discriminate early liver inflammation and fibrosis stages in patients with chronic hepatitis B

Serum alkaline phosphatase levels as a simple and useful test in screening for significant fibrosis in treatment-naive patients with hepatitis B e-antigen negative chronic hepatitis B.

Circulating Proteomic Panels For Diagnosis And Risk Stratification Of Acute-On-Chronic Liver Failure In Patients With Viral Hepatitis B

IDDF2024-ABS-0186 Analysis of the Correlation Between Gut Microbiota and Disease Severity in Patients with Primary Biliary Cholangitis

Non-invasive Diagnostic Indicators and Antiviral Treatment Efficacy in CHB Patients with Different Liver Histopathological Degrees

The Clinical Significance of the Change of Blood-Lipid in Patients with Hepatitis B-related Cirrhosis.

Predictors of Inflammatory Activity in Treatment-Naive Hepatitis B E-Antigen-negative Patients with Chronic Hepatitis B Infection

Characterization of the Circulating Microbiome in Acute-on-chronic Liver Failure Associated with Hepatitis B.

Changes of Fecal Bifidobacterium Species in Adult Patients with Hepatitis B Virus-Induced Chronic Liver Disease

A serum metabonomic study on the difference between alcohol- and HBV-induced liver cirrhosis by ultraperformance liquid chromatography coupled to mass spectrometry plus quadrupole time-of-flight mass spectrometry.

[Noninvasive Evaluation of Liver Fibrosis in Chronic Hepatitis B Patients].

Prognostic Significance of Elevated Cholestatic Enzymes for Fibrosis and Hepatocellular Carcinoma in Hospital Discharged Chronic Viral Hepatitis Patients

Modulation of bile acid profile by gut microbiota in chronic hepatitis B

Complementary Laboratory Indices for Predicting the Disease Status of Patients with Hepatitis B Virus Infection

Selected Cytokines Serve As Potential Biomarkers for Predicting Liver Inflammation and Fibrosis in Chronic Hepatitis B Patients with Normal to Mildly Elevated Aminotransferases.

Clinical significance of serum Ck18-M65 and M30 levels in patients with chronic hepatitis B combined with nonalcoholic steatohepatitis and liver fibrosis

The acousticolateralis system and ionic environments.